Characterization of V36C, a novel amino acid substitution conferring Hepatitis C Virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2681-2683

  Barbotte, Laetitia ^a   Ahmed Belkacem, Abdelhakim ^a   Chevaliez, Stéphane ^a,b   Soulier, Alexandre ^a,b   Hézode, Christophe ^a,b   Wajcman, Henri ^a   Bartels, Doug J ^c   Zhou, Yi ^c   Ardzinski, Andrzej ^c   Mani, Nagraj ^c   Rao, B Govinda ^c   George, Shelley ^c   Kwong, Ann ^c   Pawlotsky, Jean Michel ^a,b  

^a INSERM U955   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; TELAPREVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HUMANS; MODELS, MOLECULAR; MOLECULAR MIMICRY; OLIGOPEPTIDES; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77952597317     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01796-09     Document Type: Article

References (6)

1. Hézode, C., N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J. P. Bronowicki, M. Bourlière, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R. S. Kauffman, J. Alam, J. M. Pawlotsky, and S. Zeuzem. 2009. Telaprevir and peginterferon-alfa-2a with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360:1839-1850.
2. Kieffer, T. L., C. Sarrazin, J. S. Miller, M. W. Welker, N. Forestier, H. W. Reesink, A. D. Kwong, and S. Zeuzem. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639. (Pubitemid 47436107)
3. McHutchison, J. G., G. T. Everson, S. C. Gordon, I. M. Jacobson, M. Sulkowski, R. Kauffman, L. McNair, J. Alam, and A. J. Muir. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:1827-1838. [Erratum, 361:1516.]
4. Pawlotsky, J. M., S. Chevaliez, and J. G. McHutchison. 2007. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132: 1979-1998. (Pubitemid 46695724)
5. Sarrazin, C., T. L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H. M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
6. Zhou, Y., D. J. Bartels, B. L. Hanzelka, U. Muh, Y. Wei, H. M. Chu, A. M. Tigges, D. L. Brennan, B. G. Rao, L. Swenson, A. D. Kwong, and C. Lin. 2008. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52:110-120.